Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration

Abstract This was a prospective, single‐dose, single‐arm, open‐label, non‐randomized, multicenter clinical study to determine cardiovascular safety after a single brolucizumab 6 mg intravitreal injection in neovascular age‐related macular degeneration patients (N = 14). Electrocardiogram (ECG) data...

Full description

Bibliographic Details
Main Authors: Nadia Zakaria, Nicolas Guerard, Andres Emanuelli, Pravin Dugel, Jen Watts, Melissa Liew, Margarita Gekkieva, Markus Hinder
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Pharmacology Research & Perspectives
Subjects:
anti‐VEGF
brolucizumab
cardiovascular
intravitreal
nAMD
Online Access:https://doi.org/10.1002/prp2.897

Internet

https://doi.org/10.1002/prp2.897

Similar Items